A Phase 1 interventional study of Lenvatinib in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will be conducted in adult healthy participants and will consist of two phases: Prerandomization and Randomization. The Prerandomization Phase will consist of 2 periods: a Screening Period and a Baseline Period. The Randomization Phase will consist of 2 Periods (each 6 days long) separated by a 1-day long Baseline Period and End of Treatment (EOT) Period. A total of 60 participants will be enrolled into one of three arms. Arms 1 and 3 consist of 2 sequences, and Arm 2 consists of 4 sequences (as this is an incomplete block design with 2 factors [number of capsules and whether water or apple juice is used as vehicle]). Each participant will be randomized into one of 8 sequences.
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1 will have 2 sequences: 1. Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg) 2. Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)
Drug: Lenvatinib
Arm 2 will have 4 sequences: 1. Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE 2. Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER 3. Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE 4. Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER
Drug: Lenvatinib
Arm 3 will have 2 sequences: 1. Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation 2. Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation
Drug: Lenvatinib
All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
Also known as: Lenvima; E7080
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) method using a previously validated assay. The lower limit of quantitation (LLOQ) was 0.25 ng/mL. Plasma pharmacokinetics (PK) data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-t), which were then summarized as the mean and standard deviation for all participants and expressed as hours·nanogram/milliliter (hr·ng/mL).
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-inf), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))
Blood samples were collected during each Treatment Period at predose up to 24 hours post dose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-24), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
Time frame: Treatment Period 1: Predose up to 24 hours post dose
Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))
Blood samples were collected during each Treatment Period at predose up to 72 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-72), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
Time frame: Treatment Period 1: Predose up to 72 hours postdose
Apparent Clearance (CL/F)
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the CL/F, which were then summarized as the mean and standard deviation for all participants and expressed as liters/hour.
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Apparent Volume of Distribution (Vz/F)
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the Vz/F, which were then summarized as the mean and standard deviation for all participants and expressed in liters (L).
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Maximum Concentration (Cmax) of Lenvatinib in Plasma
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Cmax, which were then summarized as the mean and standard deviation for all participants and expressed as nanograms/milliliter (ng/mL).
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Time Prior to the First Measureable Concentration of Lenvatinib (Tlag)
Tlag was defined as the time delay between drug administration and the onset of drug absorption. Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tlag, which were then summarized as the median and full range for all participants and expressed in hours.
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Time to Maximum Plasma Concentration (Tmax)
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tmax, which were then summarized as the median and full range for all participants and expressed in hours.
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Terminal Elimination Phase Half-life (t1/2)
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of t1/2, which were then summarized as the median and full range for all participants and expressed in hours.
Time frame: Treatment Period 1: Day 1 (Visit 2), Day 2 (Visit 3), Days 3 to 6 (Visits 4 to 7); Treatment Period 2: Day 8 (Visit 8), Day 9 (Visit 9), Days 10 to 13 (Visits 10 to 13)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
Safety assessment consisted on monitoring and recording all treatment-emergent adverse events (TEAEs) and SAEs; as well as laboratory evaluations for hematology, blood chemistry, and urine values; periodic measurement of vital signs, electrocardiograms (ECGs); and physical examinations. A TEAE was defined as an adverse events that: 1) emerged during treatment and up to 7 days from the last treatment, having been absent before treatment or at baseline, 2) reemerged during treatment, having been present at Baseline but stopped before treatment, or 3) worsened in severity during treatment relative to the state before treatment, when continuous.
Time frame: From date of first dose of study treatment to date of last dose of study treatment, up to approximately 2 months 10 days
Summary Scores for Palatability of Lenvatinib
A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" between a) lenvatinib suspension formulated with water versus the capsule formulation, b) a lenvatinib suspension formulated with with apple juice versus one formulated with water, and c) a lenvatinib suspension formulated with water administered 23 hours versus 2 hours after preparation. All participants selected one face based on flavor, smell, sweetness, acidity, saltiness, bitterness, and texture or mouth feel for each formulation they consumed. Each face had an associated score (1: Very Bad (angry face), 2: Bad (sad face), 3: Maybe Good or Maybe Bad (neutral face), 4: Good (smiling face), 5: Very Good (laughing face)). The VAS hedonic scale scores were summarized using descriptive statistics separately for each arm by formulation (Arm 1), number of capsules (2 vs 5 capsules) and preparation type (water vs apple juice) (Arm 2), and time of administration relative to preparation (Arm 3).
Time frame: Treatment Period 1, Day 1 (Visit 2); Treatment Period 2, Day 8 (Visit 8)
| Milestone | Arm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP) | Arm 1: Lenvatinib 11 mg: CAP+ Suspension | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-Water | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-Water | Arm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 Hours | Arm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 |
| Completed | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP) | Arm 1: Lenvatinib 11 mg: CAP+ Suspension | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-Water | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-Water | Arm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 Hours | Arm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 |
| Completed | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Lenvatinib 11 mg: Suspension+ Capsules (CAP) | Arm 1: Lenvatinib 11 mg: CAP+ Suspension | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Water+2 Cap-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:5 CAP-Apple Juice+2 CAP-Water | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Water+5 CAP-Apple Juice | Arm 2:Lenvatinib 11mg Suspension:2 CAP-Apple Juice+5 CAP-Water | Arm 3:Lenvatinib 23mg Suspension Taken at:23 Hours+2 Hours | Arm 3:Lenvatinib 23mg Suspension Taken at:2 Hours+23 Hours |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 |
| Completed | 10 | 9 | 5 | 5 | 4 | 5 | 9 | 8 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 2 |
| Withdrew: Non compliance with alcohol prohibition | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Use of proscribed medications | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) method using a previously validated assay. The lower limit of quantitation (LLOQ) was 0.25 ng/mL. Plasma pharmacokinetics (PK) data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of AUC(0-t), which were then summarized as the mean and standard deviation for all participants and expressed as hours·nanogram/milliliter (hr·ng/mL).
| hr·ng/mL | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t)) | 1330 ± 452 | 1340 ± 482 | 1020 ± 172 | 1500 ± 706 | 1340 ± 519 | 1010 ± 160 | 3010 ± 919 | 3210 ± 1040 |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-inf), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
| hr·ng/mL | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf)) | 1360 ± 456 | 1360 ± 490 | 1040 ± 177 | 1530 ± 720 | 1370 ± 532 | 1030 ± 161 | 2970 ± 910 | 3240 ± 1050 |
Blood samples were collected during each Treatment Period at predose up to 24 hours post dose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-24), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
| h·ng/mL | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24)) | 1060 ± 377 | 1050 ± 383 | 815 ± 136 | 1150 ± 564 | 1070 ± 415 | 804 ± 136 | 2540 ± 785 | 2720 ± 858 |
Blood samples were collected during each Treatment Period at predose up to 72 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the AUC(0-72), which were then summarized as the mean and standard deviation for all participants and expressed as hr·ng/mL.
| hr·ng/mL | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72)) | 1280 ± 437 | 1290 ± 466 | 987 ± 164 | 1430 ± 668 | 1290 ± 500 | 971 ± 152 | 2930 ± 887 | 3130 ± 1010 |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the CL/F, which were then summarized as the mean and standard deviation for all participants and expressed as liters/hour.
| L/hour | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) | 9.34 ± 4.36 | 9.47 ± 4.45 | 10.8 ± 1.73 | 8.70 ± 3.44 | 9.10 ± 3.07 | 10.9 ± 1.61 | 8.46 ± 2.65 | 7.73 ± 2.19 |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates for the Vz/F, which were then summarized as the mean and standard deviation for all participants and expressed in liters (L).
| Liters | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 301 ± 159 | 296 ± 123 | 356 ± 74.0 | 317 ± 131 | 312 ± 122 | 360 ± 103 | 247 ± 95.7 | 238 ± 122 |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of Cmax, which were then summarized as the mean and standard deviation for all participants and expressed as nanograms/milliliter (ng/mL).
| ng/mL | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 11 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of Lenvatinib in Plasma | 133 ± 52.5 | 126 ± 44.9 | 115 ± 22.9 | 150 ± 65.2 | 138 ± 61.3 | 105 ± 21.2 | 358 ± 128 | 375 ± 134 |
Tlag was defined as the time delay between drug administration and the onset of drug absorption. Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tlag, which were then summarized as the median and full range for all participants and expressed in hours.
| Hours | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Time Prior to the First Measureable Concentration of Lenvatinib (Tlag) | 0.00 (0.00 to 0.53) | 0.00 (0.00 to 0.50) | 0.00 (0.00 to 0.50) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.50) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of tmax, which were then summarized as the median and full range for all participants and expressed in hours.
| Hours | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 3.00 (1.00 to 4.00) | 3.00 (2.00 to 4.00) | 2.52 (2.00 to 3.00) | 3.00 (2.00 to 3.00) | 2.50 (2.00 to 4.00) | 2.00 (2.00 to 3.00) | 2.00 (1.00 to 4.00) | 2.00 (1.00 to 3.00) |
Blood samples were collected during each Treatment Period at predose and at 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose. Plasma concentrations of lenvatinib were quantified by a high-performance LC-MS/MS method using a previously validated assay. The LLOQ was 0.25 ng/mL. Plasma PK data were analyzed using a non-compartmental analysis approach to obtain individual participant estimates of t1/2, which were then summarized as the median and full range for all participants and expressed in hours.
| Hours | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Terminal Elimination Phase Half-life (t1/2) | 22.7 ± 6.09 | 22.4 ± 4.67 | 23.2 ± 5.67 | 25.5 ± 4.27 | 24.1 ± 5.05 | 23.1 ± 6.15 | 20.4 ± 4.51 | 21.5 ± 7.35 |
Safety assessment consisted on monitoring and recording all treatment-emergent adverse events (TEAEs) and SAEs; as well as laboratory evaluations for hematology, blood chemistry, and urine values; periodic measurement of vital signs, electrocardiograms (ECGs); and physical examinations. A TEAE was defined as an adverse events that: 1) emerged during treatment and up to 7 days from the last treatment, having been absent before treatment or at baseline, 2) reemerged during treatment, having been present at Baseline but stopped before treatment, or 3) worsened in severity during treatment relative to the state before treatment, when continuous.
| Participants | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 4 | 6 | 1 | 2 | 4 | 4 | 3 | 4 |
| Treatment-related TEAEs | 4 | 6 | 0 | 1 | 2 | 1 | 3 | 2 |
| Severe TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Serious TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" between a) lenvatinib suspension formulated with water versus the capsule formulation, b) a lenvatinib suspension formulated with with apple juice versus one formulated with water, and c) a lenvatinib suspension formulated with water administered 23 hours versus 2 hours after preparation. All participants selected one face based on flavor, smell, sweetness, acidity, saltiness, bitterness, and texture or mouth feel for each formulation they consumed. Each face had an associated score (1: Very Bad (angry face), 2: Bad (sad face), 3: Maybe Good or Maybe Bad (neutral face), 4: Good (smiling face), 5: Very Good (laughing face)). The VAS hedonic scale scores were summarized using descriptive statistics separately for each arm by formulation (Arm 1), number of capsules (2 vs 5 capsules) and preparation type (water vs apple juice) (Arm 2), and time of administration relative to preparation (Arm 3).
| Score on a scale | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Lenvatinib 11 mg (Suspension of 5 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 5 Capsules in Juice) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Water) | Arm 2: Lenvatinib 11 mg (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| Flavor Score | 3.0 (1 to 5) | 4.0 (2 to 5) | 3.0 (1 to 5) | 4.0 (2 to 5) | 2.5 (1 to 4) | 4.0 (1 to 5) | 2.0 (1 to 5) | 2.0 (1 to 4) |
| Smell Score | 4.0 (3 to 5) | 4.0 (2 to 5) | 3.5 (2 to 5) | 4.0 (3 to 4) | 4.0 (3 to 5) | 4.0 (3 to 5) | 3.0 (1 to 5) | 3.0 (2 to 5) |
| Sweetness Score | 3.0 (1 to 5) | 3.0 (1 to 5) | 3.0 (1 to 4) | 4.0 (2 to 5) | 2.0 (1 to 4) | 4.0 (2 to 5) | 2.0 (1 to 4) | 2.0 (1 to 4) |
| Acidity Score | 3.0 (1 to 5) | 4.0 (2 to 5) | 3.0 (1 to 5) | 3.0 (2 to 4) | 2.5 (1 to 4) | 4.0 (2 to 5) | 3.0 (1 to 5) | 3.0 (1 to 4) |
| Saltiness Score | 3.0 (2 to 5) | 4.0 (1 to 5) | 3.0 (1 to 4) | 4.0 (1 to 5) | 3.0 (2 to 5) | 4.0 (2 to 5) | 3.0 (2 to 5) | 4.0 (1 to 5) |
| Bitterness Score | 3.0 (1 to 5) | 3.5 (1 to 5) | 3.0 (1 to 5) | 3.0 (2 to 4) | 3.0 (1 to 5) | 3.5 (2 to 5) | 3.0 (1 to 5) | 2.0 (1 to 5) |
| Texture or Mouth feel Score | 3.0 (1 to 5) | 3.5 (2 to 5) | 2.0 (1 to 4) | 4.0 (1 to 5) | 3.0 (1 to 5) | 4.0 (2 to 5) | 2.0 (1 to 4) | 2.0 (1 to 5) |
Collected over From date of first dose of study treatment to date of last dose of study treatment, up to approximately 2 months 10 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: 11 mg Lenvatinib Suspension in Water | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| Arm 1: 11 mg Lenvatinib Capsule With Water | 0/20 (0%) | 0/20 (0%) | 6/20 (30%) |
| Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| Event | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/19 | 1/20 | 0/10 | 1/9 | 0/10 | 0/10 | 2/18 | 0/19 |
| Heart rate decreasedInvestigations | 0/19 | 0/20 | 0/10 | 1/9 | 0/10 | 1/10 | 0/18 | 0/19 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 1/20 | 0/10 | 0/9 | 0/10 | 1/10 | 0/18 | 0/19 |
| Blood glucose decreasedInvestigations | 0/19 | 0/20 | 0/10 | 0/9 | 1/10 | 1/10 | 0/18 | 0/19 |
| Blood phosphorus decreasedInvestigations | 0/19 | 0/20 | 0/10 | 0/9 | 1/10 | 0/10 | 0/18 | 0/19 |
| Blood pressure increasedInvestigations | 0/19 | 0/20 | 0/10 | 0/9 | 1/10 | 0/10 | 0/18 | 0/19 |
| Urine analysis abnormalInvestigations | 0/19 | 0/20 | 0/10 | 0/9 | 1/10 | 1/10 | 0/18 | 0/19 |
| ErythemaSkin and subcutaneous tissue disorders | 0/19 | 0/20 | 1/10 | 0/9 | 0/10 | 0/10 | 0/18 | 0/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/19 | 1/20 | 0/10 | 0/9 | 0/10 | 0/10 | 1/18 | 1/19 |
| NauseaGastrointestinal disorders | 0/19 | 0/20 | 0/10 | 0/9 | 0/10 | 0/10 | 1/18 | 0/19 |
Safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.
| Age, Customized(Participants) | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) | Total |
|---|---|---|---|---|---|---|---|---|---|
| 18 to 65 years | 10 | 10 | 5 | 5 | 5 | 5 | 10 | 10 | 60 |
| Sex/Gender, Customized(Participants) | Arm 1: 11 mg Lenvatinib Suspension in Water | Arm 1: 11 mg Lenvatinib Capsule With Water | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 5 Capsules in Juice) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Water) | Arm 2: 11 mg Lenvatinib (Suspension of 2 Capsules in Juice) | Arm 3: 23 mg Lenvatinib Suspension in Water (23 Hours) | Arm 3: 23 mg Lenvatinib Suspension in Water (2 Hours) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male | 9 | 7 | 5 | 3 | 3 | 3 | 5 | 7 | 42 |
| Female | 1 | 3 | 0 | 2 | 2 | 2 | 5 | 3 | 18 |
The record gives a start of Aug 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib